Current Research Studies

PNOC026: DAY101-001/FIREFLY01 - A Phase 2, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

PNOC026

  • Condition(s): Adrenal Tumors, Brain Tumor, High-Grade Glioma, Histiocytic Tumors, Langerhans Cell Histiocytosis (LCH), Liver Tumors, Low-Grade Glioma, Pilocytic Astrocytoma, Recurrent and/or Refractory, Soft Tissue Sarcomas, Solid Tumor, Thyroid Cancer
  • Phase: II
  • Clinicaltrials.gov ID: NCT04775485

What is the goal of the study?

To evaluate the overall response rate (ORR) as determined by an independent radiology review committee (IRC) and measured by the proportion of patients with best overall confirmed response of complete response (CR) or partial response (PR) by Response Assessment in Neuro-Oncology (RANO) criteria following treatment with DAY101 in pediatric patients aged 6 months to 25 years of age with a relapsed or progressive low-grade glioma (LGG) harboring a known activating BRAF alteration

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: